Skip to main content
SpringerLink
Log in
Book cover

Melatonin and Melatonergic Drugs in Clinical Practice pp 1–15Cite as

Melatonin Receptors and Their Role in Human Diseases

  • Chapter
  • First Online:

Abstract

Melatonin acts mostly through G-protein-coupled plasma membrane receptors. MT1 and MT2 are the two functional melatonin membrane receptors. They are expressed in various organs of all mammals, including humans. The functional meaning of the receptors in the various organs is still not sufficiently investigated. This chapter summarizes the currently available data about MT1 and MT2 receptors in human tissues and human cells. Established and putative functions of melatonin after receptor activation will be described, and the clinical relevance of these findings will be discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc. 1958;80:2057–8.

    Google Scholar 

  2. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9(1):11–24.

    PubMed  Google Scholar 

  3. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991;12(2):151–80.

    CAS  PubMed  Google Scholar 

  4. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. 2003;34(1):1–10.

    CAS  PubMed  Google Scholar 

  5. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25(3–4):177–95.

    CAS  PubMed  Google Scholar 

  6. Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC, Leon J, et al. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol. 2004;56(2):159–70.

    CAS  PubMed  Google Scholar 

  7. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36(1):1–9.

    CAS  PubMed  Google Scholar 

  8. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34(1):75–8.

    CAS  PubMed  Google Scholar 

  9. Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, et al. Melatonin signaling and cell protection function. FASEB J. 2010;24(10):3603–24.

    CAS  PubMed  Google Scholar 

  10. Benitez-King G, Anton-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia. 1993;49(8):635–41.

    CAS  PubMed  Google Scholar 

  11. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005;38(4):217–22.

    CAS  PubMed  Google Scholar 

  12. Carrillo-Vico A, Lardone PJ, Fernandez-Santos JM, Martin-Lacave I, Calvo JR, Karasek M, et al. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metab. 2005;90(2):992–1000.

    CAS  PubMed  Google Scholar 

  13. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Goberna R, Guerrero JM. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J Neuroimmunol. 1998;92(1–2):76–84.

    CAS  PubMed  Google Scholar 

  14. Steinhilber D, Brungs M, Werz O, Wiesenberg I, Danielsson C, Kahlen JP, et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem. 1995;270(13):7037–40.

    CAS  PubMed  Google Scholar 

  15. Abel J, Haarmann-Stemmann T. An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem. 2010;391(11):1235–48.

    CAS  PubMed  Google Scholar 

  16. Shimba S, Watabe Y. Crosstalk between the AHR signaling pathway and circadian rhythm. Biochem Pharmacol. 2009;77(4):560–5.

    CAS  PubMed  Google Scholar 

  17. Anisimov SV, Popovic N. Genetic aspects of melatonin biology. Rev Neurosci. 2004;15(3):209–30.

    CAS  PubMed  Google Scholar 

  18. Barrett P, Conway S, Morgan PJ. Digging deep – structure-function relationships in the melatonin receptor family. J Pineal Res. 2003;35(4):221–30.

    CAS  PubMed  Google Scholar 

  19. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8:d1093–108.

    CAS  PubMed  Google Scholar 

  20. Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE. 2001;2001(107):E39.

    Google Scholar 

  21. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309(1):151–62.

    Google Scholar 

  22. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci. 2003;72(20):2183–98.

    CAS  PubMed  Google Scholar 

  23. Aust S, Thalhammer T, Humpeler S, Jager W, Klimpfinger M, Tucek G, et al. The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J Pineal Res. 2004;36(1):43–8.

    CAS  PubMed  Google Scholar 

  24. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60(3):97–108.

    CAS  PubMed  Google Scholar 

  25. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001;21(1):85–91.

    CAS  PubMed  Google Scholar 

  26. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. 24 h variation in the expression of the mt1 melatonin receptor subtype in coronary arteries derived from patients with coronary heart disease. Chronobiol Int. 2001;18(6):973–85.

    CAS  PubMed  Google Scholar 

  27. Ekmekcioglu C, Thalhammer T, Humpeler S, Mehrabi MR, Glogar HD, Holzenbein T, et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res. 2003;35(1):40–4.

    CAS  PubMed  Google Scholar 

  28. Nemeth C, Humpeler S, Kallay E, Mesteri I, Svoboda M, Rogelsperger O, et al. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. J Biol Regul Homeost Agents. 2011;25(4):531–42.

    CAS  PubMed  Google Scholar 

  29. Rogelsperger O, Ekmekcioglu C, Jager W, Klimpfinger M, Konigsberg R, Krenbek D, et al. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009;46(4):422–32.

    CAS  PubMed  Google Scholar 

  30. Rogelsperger O, Wlcek K, Ekmekcioglu C, Humpeler S, Svoboda M, Konigsberg R, et al. Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. J Recept Signal Transduct Res. 2011;31(2):180–7.

    PubMed  Google Scholar 

  31. Toma CD, Svoboda M, Arrich F, Ekmekcioglu C, Assadian O, Thalhammer T. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res. 2007;43(2):206–13.

    CAS  PubMed  Google Scholar 

  32. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010;62(3):343–80.

    CAS  PubMed  Google Scholar 

  33. Delagrange P, Atkinson J, Boutin JA, Casteilla L, Lesieur D, Misslin R, et al. Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrinol. 2003;15(4):442–8.

    CAS  PubMed  Google Scholar 

  34. Tarzia G, Diamantini G, Mor M, Spadoni G. Design and synthesis of melatonin receptors agonists and antagonists. Farmaco. 2000;55(3):184–7.

    CAS  PubMed  Google Scholar 

  35. Witt-Enderby PA, Li PK. Melatonin receptors and ligands. Vitam Horm. 2000;58:321–54.

    CAS  PubMed  Google Scholar 

  36. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm (Weinheim). 2005;338(5–6):229–47.

    CAS  Google Scholar 

  37. New DC, Tsim ST, Wong YH. G protein-linked effector and second messenger systems involved in melatonin signal transduction. Neurosignals. 2003;12(2):59–70.

    CAS  PubMed  Google Scholar 

  38. von Gall C, Weaver DR, Kock M, Korf HW, Stehle JH. Melatonin limits transcriptional impact of phosphoCREB in the mouse SCN via the Mel1a receptor. Neuroreport. 2000;11(9):1803–7.

    Google Scholar 

  39. Witt-Enderby PA, MacKenzie RS, McKeon RM, Carroll EA, Bordt SL, Melan MA. Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor. Cell Motil Cytoskeleton. 2000;46(1):28–42.

    CAS  PubMed  Google Scholar 

  40. Hill SM, Blask DE, Xiang S, Yuan L, Mao L, Dauchy RT, et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia. 2011;16(3):235–45.

    PubMed  Google Scholar 

  41. Godson C, Reppert SM. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology. 1997;138(1):397–404.

    CAS  PubMed  Google Scholar 

  42. Roka F, Brydon L, Waldhoer M, Strosberg AD, Freissmuth M, Jockers R, et al. Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity. Mol Pharmacol. 1999;56(5):1014–24.

    CAS  PubMed  Google Scholar 

  43. Geary GG, Duckles SP, Krause DN. Effect of melatonin in the rat tail artery: role of K+ channels and endothelial factors. Br J Pharmacol. 1998;123(8):1533–40.

    CAS  PubMed  Google Scholar 

  44. Jiang ZG, Nelson CS, Allen CN. Melatonin activates an outward current and inhibits Ih in rat suprachiasmatic nucleus neurons. Brain Res. 1995;687(1–2):125–32.

    CAS  PubMed  Google Scholar 

  45. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92(19):8734–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Petit L, Lacroix I, de Coppet P, Strosberg AD, Jockers R. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol. 1999;58(4):633–9.

    CAS  PubMed  Google Scholar 

  47. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001;280(1):C110–8.

    CAS  PubMed  Google Scholar 

  48. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem. 2002;277(24):21522–8.

    CAS  PubMed  Google Scholar 

  49. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351(2):152–66.

    CAS  PubMed Central  PubMed  Google Scholar 

  50. Paul P, Lahaye C, Delagrange P, Nicolas JP, Canet E, Boutin JA. Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther. 1999;290(1):334–40.

    CAS  PubMed  Google Scholar 

  51. Mailliet F, Ferry G, Vella F, Thiam K, Delagrange P, Boutin JA. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett. 2004;578(1–2):116–20.

    CAS  PubMed  Google Scholar 

  52. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275(40):31311–7.

    CAS  PubMed  Google Scholar 

  53. Pintor J, Pelaez T, Hoyle CH, Peral A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol. 2003;138(5):831–6.

    CAS  PubMed  Google Scholar 

  54. Reppert SM, Weaver DR, Ebisawa T, Mahle CD, Kolakowski Jr LF. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. 1996;386(2–3):219–24.

    CAS  PubMed  Google Scholar 

  55. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P, et al. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 2006;25(13):3012–23.

    CAS  PubMed  Google Scholar 

  56. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, et al. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol. 2003;23(3):1054–60.

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19(1):91–102.

    CAS  PubMed  Google Scholar 

  58. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49.

    CAS  PubMed  Google Scholar 

  59. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin – a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350–84.

    CAS  PubMed  Google Scholar 

  60. Maywood ES, O’Neill J, Wong GK, Reddy AB, Hastings MH. Circadian timing in health and disease. Prog Brain Res. 2006;153:253–69.

    CAS  PubMed  Google Scholar 

  61. Okamura H, Doi M, Fustin JM, Yamaguchi Y, Matsuo M. Mammalian circadian clock system: molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev. 2010;62(9–10):876–84.

    CAS  PubMed  Google Scholar 

  62. Imbesi M, Arslan AD, Yildiz S, Sharma R, Gavin D, Tun N, et al. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal ‘clock’ gene expression in striatal neurons in vitro. J Pineal Res. 2009;46(1):87–94.

    CAS  PubMed  Google Scholar 

  63. Weaver DR, Reppert SM. The Mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport. 1996;8(1):109–12.

    CAS  PubMed  Google Scholar 

  64. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15(4):432–7.

    CAS  PubMed  Google Scholar 

  65. Korf HW, Von Gall C, Stehle J. The circadian system and melatonin: lessons from rats and mice. Chronobiol Int. 2003;20(4):697–710.

    CAS  PubMed  Google Scholar 

  66. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380–92.

    CAS  PubMed  Google Scholar 

  67. Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms. 1997;12(6):604–17.

    CAS  PubMed  Google Scholar 

  68. Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000;343(15):1070–7.

    CAS  PubMed  Google Scholar 

  69. Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17(6):733–41.

    CAS  PubMed  Google Scholar 

  70. van den Heuvel CJ, Ferguson SA, Macchi MM, Dawson D. Melatonin as a hypnotic: con. Sleep Med Rev. 2005;9(1):71–80.

    PubMed  Google Scholar 

  71. Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev. 2005;9(1):51–65.

    PubMed  Google Scholar 

  72. Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem. 2002;45(19):4222–39.

    CAS  PubMed  Google Scholar 

  73. Wu YH, Ursinus J, Zhou JN, Scheer FA, Ai-Min B, Jockers R, et al. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord. 2013;148(2–3):357–67.

    CAS  PubMed  Google Scholar 

  74. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378(9791):621–31.

    CAS  PubMed  Google Scholar 

  75. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954–64.

    CAS  PubMed  Google Scholar 

  76. Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer’s disease. J Pineal Res. 2005;38(1):10–6.

    CAS  PubMed  Google Scholar 

  77. Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R, et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer’s disease patients. J Pineal Res. 2002;32(1):59–62.

    PubMed  Google Scholar 

  78. Hogan MV, El-Sherif Y, Wieraszko A. The modulation of neuronal activity by melatonin: in vitro studies on mouse hippocampal slices. J Pineal Res. 2001;30(2):87–96.

    CAS  PubMed  Google Scholar 

  79. Musshoff U, Riewenherm D, Berger E, Fauteck JD, Speckmann EJ. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus. 2002;12(2):165–73.

    CAS  PubMed  Google Scholar 

  80. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett. 2002;23 Suppl 1:20–3.

    CAS  PubMed  Google Scholar 

  81. Fauteck J, Schmidt H, Lerchl A, Kurlemann G, Wittkowski W. Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol Signals Recept. 1999;8(1–2):105–10.

    CAS  PubMed  Google Scholar 

  82. de Lima E, Soares Jr JM, del Carmen Sanabria Garrido Y, Gomes Valente S, Priel MR, Chada Baracat E, et al. Effects of pinealectomy and the treatment with melatonin on the temporal lobe epilepsy in rats. Brain Res. 2005;1043(1–2):24–31.

    PubMed  Google Scholar 

  83. Stewart LS, Leung LS. Hippocampal melatonin receptors modulate seizure threshold. Epilepsia. 2005;46(4):473–80.

    CAS  PubMed  Google Scholar 

  84. Uz T, Arslan AD, Kurtuncu M, Imbesi M, Akhisaroglu M, Dwivedi Y, et al. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res. 2005;136(1–2):45–53.

    CAS  PubMed  Google Scholar 

  85. Sircar R. Effect of melatonin on cocaine-induced behavioral sensitization. Brain Res. 2000;857(1–2):295–9.

    CAS  PubMed  Google Scholar 

  86. Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med Sci Monit. 2010;16(2):BR61–7.

    CAS  PubMed  Google Scholar 

  87. Scher J, Wankiewicz E, Brown GM, Fujieda H. MT(1) melatonin receptor in the human retina: expression and localization. Invest Ophthalmol Vis Sci. 2002;43(3):889–97.

    PubMed  Google Scholar 

  88. Iuvone PM, Tosini G, Pozdeyev N, Haque R, Klein DC, Chaurasia SS. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res. 2005;24(4):433–56.

    CAS  PubMed  Google Scholar 

  89. Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res. 2012;103:82–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Djamgoz MB, Wagner HJ. Localization and function of dopamine in the adult vertebrate retina. Neurochem Int. 1992;20(2):139–91.

    CAS  PubMed  Google Scholar 

  91. Alarma-Estrany P, Crooke A, Mediero A, Pelaez T, Pintor J. Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits. J Pineal Res. 2008;45(4):468–75.

    CAS  PubMed  Google Scholar 

  92. Belforte NA, Moreno MC, de Zavalia N, Sande PH, Chianelli MS, Keller Sarmiento MI, et al. Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res. 2010;48(4):353–64.

    CAS  PubMed  Google Scholar 

  93. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, Rosenstein RE. Melatonin in the eye: implications for glaucoma. Exp Eye Res. 2007;84(6):1021–30.

    CAS  PubMed  Google Scholar 

  94. Pintor J, Martin L, Pelaez T, Hoyle CH, Peral A. Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol. 2001;416(3):251–4.

    CAS  PubMed  Google Scholar 

  95. Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg. 2009;108(4):1146–51.

    CAS  PubMed  Google Scholar 

  96. Abete P, Bianco S, Calabrese C, Napoli C, Cacciatore F, Ferrara N, et al. Effects of melatonin in isolated rat papillary muscle. FEBS Lett. 1997;412(1):79–85.

    CAS  PubMed  Google Scholar 

  97. Pang CS, Xi SC, Brown GM, Pang SF, Shiu SY. 2[125I]Iodomelatonin binding and interaction with beta-adrenergic signaling in chick heart/coronary artery physiology. J Pineal Res. 2002;32(4):243–52.

    CAS  PubMed  Google Scholar 

  98. Mei YA, Lee PP, Wei H, Zhang ZH, Pang SF. Melatonin and its analogs potentiate the nifedipine-sensitive high-voltage-activated calcium current in the chick embryonic heart cells. J Pineal Res. 2001;30(1):13–21.

    CAS  PubMed  Google Scholar 

  99. Viswanathan M, Laitinen JT, Saavedra JM. Expression of melatonin receptors in arteries involved in thermoregulation. Proc Natl Acad Sci U S A. 1990;87(16):6200–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Yang Q, Scalbert E, Delagrange P, Vanhoutte PM, O’Rourke ST. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2001;280(1):H76–82.

    CAS  PubMed  Google Scholar 

  101. Regrigny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I. Melatonin improves cerebral circulation security margin in rats. Am J Physiol. 1998;275(1 Pt 2):H139–44.

    CAS  PubMed  Google Scholar 

  102. Masana MI, Doolen S, Ersahin C, Al-Ghoul WM, Duckles SP, Dubocovich ML, et al. MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther. 2002;302(3):1295–302.

    CAS  PubMed  Google Scholar 

  103. Schepelmann M, Molcan L, Uhrova H, Zeman M, Ellinger I. The presence and localization of melatonin receptors in the rat aorta. Cell Mol Neurobiol. 2011;31(8):1257–65.

    CAS  PubMed  Google Scholar 

  104. Monroe KK, Watts SW. The vascular reactivity of melatonin. Gen Pharmacol. 1998;30(1):31–5.

    CAS  PubMed  Google Scholar 

  105. Weekley LB. Pharmacologic studies on the mechanism of melatonin-induced vasorelaxation in rat aorta. J Pineal Res. 1995;19(3):133–8.

    CAS  PubMed  Google Scholar 

  106. Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: effects of postural change and melatonin administration. J Appl Physiol. 1997;83(1):134–9.

    CAS  PubMed  Google Scholar 

  107. van den Heuvel CJ, Kennaway DJ, Dawson D. Thermoregulatory and soporific effects of very low dose melatonin injection. Am J Physiol. 1999;276(2 Pt 1):E249–54.

    PubMed  Google Scholar 

  108. van der Helm-van Mil AH, van Someren EJ, van den Boom R, van Buchem MA, de Craen AJ, Blauw GJ. No influence of melatonin on cerebral blood flow in humans. J Clin Endocrinol Metab. 2003;88(12):5989–94.

    PubMed  Google Scholar 

  109. Cook JS, Sauder CL, Ray CA. Melatonin differentially affects vascular blood flow in humans. Am J Physiol Heart Circ Physiol. 2011;300(2):H670–4.

    CAS  PubMed  Google Scholar 

  110. Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol. 1999;83(9):1417–9.

    CAS  PubMed  Google Scholar 

  111. Cagnacci A, Arangino S, Angiolucci M, Melis GB, Facchinetti F, Malmusi S, et al. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin Endocrinol (Oxf). 2001;54(2):261–6.

    CAS  Google Scholar 

  112. Gilad E, Laudon M, Matzkin H, Pick E, Sofer M, Braf Z, et al. Functional melatonin receptors in human prostate epithelial cells. Endocrinology. 1996;137(4):1412–7.

    CAS  PubMed  Google Scholar 

  113. Laudon M, Gilad E, Matzkin H, Braf Z, Zisapel N. Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab. 1996;81(4):1336–42.

    CAS  PubMed  Google Scholar 

  114. Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate. 2002;52(2):106–22.

    CAS  PubMed  Google Scholar 

  115. Tam CW, Shiu SY. Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res. 2011;51(3):297–312.

    CAS  PubMed  Google Scholar 

  116. Xi SC, Tam PC, Brown GM, Pang SF, Shiu SY. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res. 2000;29(3):172–83.

    CAS  PubMed  Google Scholar 

  117. Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res. 2003;35(3):177–82.

    CAS  PubMed  Google Scholar 

  118. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273–84.

    PubMed  Google Scholar 

  119. Hansen J, Lassen CF. Nested case–control study of night shift work and breast cancer risk among women in the Danish military. Occup Environ Med. 2012;69(8):551–6.

    PubMed  Google Scholar 

  120. Reed VA. Shift work, light at night, and the risk of breast cancer. AAOHN J. 2011;59(1):37–45; quiz 6.

    PubMed  Google Scholar 

  121. Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, et al. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002;118(3):451–8.

    CAS  PubMed  Google Scholar 

  122. Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: a short review. Endocr Relat Cancer. 2003;10(2):153–9.

    CAS  PubMed  Google Scholar 

  123. Cos S, Gonzalez A, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 2006;30(2):118–28.

    CAS  PubMed  Google Scholar 

  124. Girgert R, Hanf V, Emons G, Grundker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res. 2009;47(1):23–31.

    CAS  PubMed  Google Scholar 

  125. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002;192(1–2):147–56.

    CAS  PubMed  Google Scholar 

  126. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995;71(4):854–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  127. Seron-Ferre M, Ducsay CA, Valenzuela GJ. Circadian rhythms during pregnancy. Endocr Rev. 1993;14(5):594–609.

    CAS  PubMed  Google Scholar 

  128. Panduro-Baron G, Gonzalez-Moreno J, Hernandez-Figueroa E. The biorhythm of birth. Int J Gynaecol Obstet. 1994;45(3):283–4.

    CAS  PubMed  Google Scholar 

  129. Schlabritz-Loutsevitch N, Hellner N, Middendorf R, Muller D, Olcese J. The human myometrium as a target for melatonin. J Clin Endocrinol Metab. 2003;88(2):908–13.

    CAS  PubMed  Google Scholar 

  130. Ayar A, Kutlu S, Yilmaz B, Kelestimur H. Melatonin inhibits spontaneous and oxytocin-induced contractions of rat myometrium in vitro. Neuro Endocrinol Lett. 2001;22(3):199–207.

    CAS  PubMed  Google Scholar 

  131. Martensson LG, Andersson RG, Berg G. Melatonin together with noradrenaline augments contractions of human myometrium. Eur J Pharmacol. 1996;316(2–3):273–5.

    CAS  PubMed  Google Scholar 

  132. Sharkey JT, Puttaramu R, Word RA, Olcese J. Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells. J Clin Endocrinol Metab. 2009;94(2):421–7.

    CAS  PubMed  Google Scholar 

  133. Voordouw BC, Euser R, Verdonk RE, Alberda BT, de Jong FH, Drogendijk AC, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab. 1992;74(1):108–17.

    CAS  PubMed  Google Scholar 

  134. Luboshitzky R, Shen-Orr Z, Shochat T, Herer P, Lavie P. Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil. J Mol Neurosci. 1999;12(1):75–80.

    CAS  PubMed  Google Scholar 

  135. Luboshitzky R, Lavie P. Melatonin and sex hormone interrelationships – a review. J Pediatr Endocrinol Metab. 1999;12(3):355–62.

    CAS  PubMed  Google Scholar 

  136. Yie SM, Niles LP, Younglai EV. Melatonin receptors on human granulosa cell membranes. J Clin Endocrinol Metab. 1995;80(5):1747–9.

    CAS  PubMed  Google Scholar 

  137. Woo MM, Tai CJ, Kang SK, Nathwani PS, Pang SF, Leung PC. Direct action of melatonin in human granulosa-luteal cells. J Clin Endocrinol Metab. 2001;86(10):4789–97.

    CAS  PubMed  Google Scholar 

  138. Nathwani PS, Kang SK, Cheng KW, Choi KC, Leung PC. Regulation of gonadotropin-releasing hormone and its receptor gene expression by 17beta-estradiol in cultured human granulosa-luteal cells. Endocrinology. 2000;141(5):1754–63.

    CAS  PubMed  Google Scholar 

  139. Raikhlin NT, Kvetnoy IM, Tolkachev VN. Melatonin may be synthesised in enterochromaffin cells. Nature. 1975;255(5506):344–5.

    CAS  PubMed  Google Scholar 

  140. Bubenik GA. Localization of melatonin in the digestive tract of the rat. Effect of maturation, diurnal variation, melatonin treatment and pinealectomy. Horm Res. 1980;12(6):313–23.

    CAS  PubMed  Google Scholar 

  141. Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol. 2008;59 Suppl 2:33–51.

    PubMed  Google Scholar 

  142. Messner M, Huether G, Lorf T, Ramadori G, Schworer H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci. 2001;69(5):543–51.

    CAS  PubMed  Google Scholar 

  143. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47(10):2336–48.

    CAS  PubMed  Google Scholar 

  144. Bubenik GA. The effect of serotonin, N-acetylserotonin, and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res. 1986;3(1):41–54.

    CAS  PubMed  Google Scholar 

  145. Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, et al. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res. 2002;33(2):101–8.

    CAS  PubMed  Google Scholar 

  146. Sjoblom M, Flemstrom G. Melatonin in the duodenal lumen is a potent stimulant of mucosal bicarbonate secretion. J Pineal Res. 2003;34(4):288–93.

    CAS  PubMed  Google Scholar 

  147. Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion. J Clin Invest. 2001;108(4):625–33.

    CAS  PubMed Central  PubMed  Google Scholar 

  148. Sjoblom M, Flemstrom G. Central nervous alpha1-adrenoceptor stimulation induces duodenal luminal release of melatonin. J Pineal Res. 2004;36(2):103–8.

    PubMed  Google Scholar 

  149. Sjoblom M, Safsten B, Flemstrom G. Melatonin-induced calcium signaling in clusters of human and rat duodenal enterocytes. Am J Physiol Gastrointest Liver Physiol. 2003;284(6):G1034–44.

    PubMed  Google Scholar 

  150. Jaworek J, Nawrot-Porabka K, Leja-Szpak A, Bonior J, Szklarczyk J, Kot M, et al. Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 2007;58 Suppl 6:65–80.

    PubMed  Google Scholar 

  151. Brzozowska I, Ptak-Belowska A, Pawlik M, Pajdo R, Drozdowicz D, Konturek SJ, et al. Mucosal strengthening activity of central and peripheral melatonin in the mechanism of gastric defense. J Physiol Pharmacol. 2009;60 Suppl 7:47–56.

    PubMed  Google Scholar 

  152. Celinski K, Konturek SJ, Konturek PC, Brzozowski T, Cichoz-Lach H, Slomka M, et al. Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res. 2011;50(4):389–94.

    CAS  PubMed  Google Scholar 

  153. Ganguly K, Sharma AV, Reiter RJ, Swarnakar S. Melatonin promotes angiogenesis during protection and healing of indomethacin-induced gastric ulcer: role of matrix metaloproteinase-2. J Pineal Res. 2010;49(2):130–40.

    CAS  PubMed  Google Scholar 

  154. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J, Szczesniewski A, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J. 2002;16(8):896–8.

    CAS  PubMed  Google Scholar 

  155. Slominski A, Pisarchik A, Zbytek B, Tobin DJ, Kauser S, Wortsman J. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol. 2003;196(1):144–53.

    CAS  PubMed  Google Scholar 

  156. Roberts JE, Wiechmann AF, Hu DN. Melatonin receptors in human uveal melanocytes and melanoma cells. J Pineal Res. 2000;28(3):165–71.

    CAS  PubMed  Google Scholar 

  157. Hu DN, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res. 1997;7(1):27–31.

    CAS  PubMed  Google Scholar 

  158. Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol. 1993;246(2):89–96.

    CAS  PubMed  Google Scholar 

  159. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J. 2005;19(2):176–94.

    CAS  PubMed  Google Scholar 

  160. Kleszczynski K, Fischer TW. Melatonin and human skin aging. Dermatoendocrinol. 2012;4(3):245–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  161. Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150(2):341–5.

    CAS  PubMed  Google Scholar 

  162. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem. 2002;2(2):167–79.

    CAS  PubMed  Google Scholar 

  163. Csaba G, Barath P. Morphological changes of thymus and the thyroid gland after postnatal extirpation of pineal body. Endocrinol Exp. 1975;9(1):59–67.

    CAS  PubMed  Google Scholar 

  164. Carrillo-Vico A, Lardone PJ, Alvarez-Sanchez N, Rodriguez-Rodriguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci. 2013;14(4):8638–83.

    CAS  PubMed Central  PubMed  Google Scholar 

  165. Liu F, Ng TB, Fung MC. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J Neural Transm. 2001;108(4):397–405.

    CAS  PubMed  Google Scholar 

  166. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol. 1997;159(2):574–81.

    CAS  PubMed  Google Scholar 

  167. Morrey KM, McLachlan JA, Serkin CD, Bakouche O. Activation of human monocytes by the pineal hormone melatonin. J Immunol. 1994;153(6):2671–80.

    CAS  PubMed  Google Scholar 

  168. Pozo D, Garcia-Maurino S, Guerrero JM, Calvo JR. MRNA expression of nuclear receptor RZR/RORalpha, melatonin membrane receptor MT, and hydroxyindole-O-methyltransferase in different populations of human immune cells. J Pineal Res. 2004;37(1):48–54.

    CAS  PubMed  Google Scholar 

  169. Carrillo-Vico A, Garcia-Perganeda A, Naji L, Calvo JR, Romero MP, Guerrero JM. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci. 2003;60(10):2272–8.

    CAS  PubMed  Google Scholar 

  170. Heldmaier G, Hoffmann K. Melatonin stimulates growth of brown adipose tissue. Nature. 1974;247(438):224–5.

    CAS  PubMed  Google Scholar 

  171. Le Gouic S, Delagrange P, Atgie C, Nibbelink M, Hanoun N, Casteilla L, et al. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int J Obes Relat Metab Disord. 1996;20(7):661–7.

    PubMed  Google Scholar 

  172. Viswanathan M, Hissa R, George JC. Effects of short photoperiod and melatonin treatment on thermogenesis in the Syrian hamster. J Pineal Res. 1986;3(4):311–21.

    CAS  PubMed  Google Scholar 

  173. Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev. 2011;12(3):167–88.

    CAS  PubMed  Google Scholar 

  174. Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology. 2003;144(12):5347–52.

    CAS  PubMed  Google Scholar 

  175. Rios-Lugo MJ, Cano P, Jimenez-Ortega V, Fernandez-Mateos MP, Scacchi PA, Cardinali DP, et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J Pineal Res. 2010;49(4):342–8.

    CAS  PubMed  Google Scholar 

  176. Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, et al. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(1):11–25.

    CAS  PubMed  Google Scholar 

  177. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50(3):261–6.

    CAS  PubMed  Google Scholar 

  178. Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R. Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology. 2001;142(10):4264–71.

    CAS  PubMed  Google Scholar 

  179. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981–7015.

    CAS  PubMed Central  PubMed  Google Scholar 

  180. Peschke E, Schucht H, Muhlbauer E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. J Pineal Res. 2010;49(4):373–81.

    CAS  PubMed  Google Scholar 

  181. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89–94.

    CAS  PubMed  Google Scholar 

  182. Chambers JC, Zhang W, Zabaneh D, Sehmi J, Jain P, McCarthy MI, et al. Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians. Diabetes. 2009;58(11):2703–8.

    CAS  PubMed  Google Scholar 

  183. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  184. Xia Q, Chen ZX, Wang YC, Ma YS, Zhang F, Che W, et al. Association between the melatonin receptor 1B gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis. PLoS One. 2012;7(11):e50107.

    CAS  PubMed Central  PubMed  Google Scholar 

  185. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34(9):709–31.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Environmental Health, Medical University Vienna, Kinderspitalgasse 15, Vienna, 1090, Austria

    Cem Ekmekcioglu MD

  2. Department of Pathophysiology and Allergy Research (IPA), AKH, Waehringer Guertel 18-20, Vienna, A-1090, Austria

    Theresia Thalhammer PhD

Authors
  1. Cem Ekmekcioglu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theresia Thalhammer PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cem Ekmekcioglu MD .

Editor information

Editors and Affiliations

  1. Sri Sathya Sai Medical Educational and Research Foundation, An International Medical Sciences Research Center, Coimbatore, Tamil Nadu, India

    V. Srinivasan

  2. Department of Obstetrics and Gynecology, Hadassah Hebrew-University Medical Center, Jerusalem, Israel

    Amnon Brzezinski

  3. Department of Physiology, Gulhane Military Medical Academy, Ankara, Turkey

    Sukru Oter

  4. Department of Psychiatry Behavioral Sciences, Mercer University School of Medicine, Macon, Georgia, USA

    Samuel D. Shillcutt

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer India

About this chapter

Cite this chapter

Ekmekcioglu, C., Thalhammer, T. (2014). Melatonin Receptors and Their Role in Human Diseases. In: Srinivasan, V., Brzezinski, A., Oter, S., Shillcutt, S. (eds) Melatonin and Melatonergic Drugs in Clinical Practice. Springer, New Delhi. https://doi.org/10.1007/978-81-322-0825-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-0825-9_1

  • Published:

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-0824-2

  • Online ISBN: 978-81-322-0825-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation